SecBot SecBot
144 ·Filed May 21, 2026

BBIO

BridgeBio Pharma, Inc.
NEUTRAL
Impact 3/10
Horizondays Processed5mo ago SEC0001950047-26-004909
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This Form 144 is a continuation of a high-cadence but mechanically pre-planned 10b5-1 selling program by the CEO in two trusts. The predictable weekly pace and fixed lot size suggest a liquidity or tax-planning strategy rather than a reactive signal. No earnings or binary catalyst is imminent (next quarterly filing would be ~August 2026). Traders should not read this as bearish, the pattern has been in place for over two months. No action warranted.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$69.12
T+0 close · May 21, 2026 · via day close
Latest settled
+20.05%
T+60 · $82.98
Vs SPY
+16.86%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · May 22 $69.12entry
  2. T+1 · 6mo ago −2.01%α −2.60% · $67.73
  3. T+5 · 6mo ago −5.44%α −7.10% · $65.36
  4. T+20 · 5mo ago −0.35%α +1.07% · $68.88
  5. T+60 · 3mo ago +20.05%α +16.86% · $82.98

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio Pharma CEO Neil Kumar filed a Form 144 on May 21, 2026, indicating intent to sell 26,103 shares of common stock valued at approximately $1.78 million. The filing discloses that the proposed sale will be executed through the Kumar Haldea Revocable Trust and/or Family Irrevocable Trust, both of which Kumar manages. The filing references a pre-existing Rule 10b5-1 trading plan, and Kumar has sold similar blocks of 20,000 shares per trade nearly every week since mid-March across these trusts, these sales are routine and pre-planned, not a reactive insider signal.

Key Facts

  • CEO Neil Kumar filed Form 144 proposing to sell 26,103 shares of BBIO common stock on or after May 21, 2026.
  • Estimated proceeds of the proposed sale are $1,780,746.66 based on the filing date price of ~$68.22/share.
  • The filing notes that the sale will be executed under pre-existing Rule 10b5-1 trading plans for the Kumar Haldea Revocable Trust and Family Irrevocable Trust.
  • Since mid-March 2026, Kumar has sold 20,000-share blocks (fixed lots of ~$1.3-1.5M) approximately weekly across both trusts, this filing is a continuation of that cadence.
  • Recent insider activity totals $2.0M in sells over the past 30 days across 3 transactions, consistent with the pattern.
  • Market cap is $13.4B; the proposed sale represents only ~0.002% of shares outstanding.

Financial Impact

Proposed sale of 26,103 shares at ~$1.78M, representing approximately 0.002% of market cap, immaterial in absolute terms.

insider holdingstrading volume

Risk Factors

  • Insiders using 10b5-1 plans can still cancel or modify them; a persistent high-volume sell program could eventually signal fading conviction if fundamentals deteriorate.
  • The $13.4B market cap is supported by 97% analyst buy ratings; any pipeline setback could make routine insider selling look more opportunistic in hindsight.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
97% bullish (30 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-004909
Document: 0001950047-26-004909-index.html0001950047-26-004909
Document: 0001950047-26-004909.txt0001950047-26-004909

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h 4m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published May 21, 2026